KKR completed the acquisition of Biotage for SEK11.6bn.

KKR, a global investment firm, completed the acquisition of Biotage, a drug discovery and development, diagnostics and analytical testing solutions provider, for SEK11.6bn. "We are pleased to complete this transaction with support from shareholders representing over 90 percent of the shares. Our investment will continue KKR's long-term support for Biotage, leveraging our sector knowledge and resources to facilitate the company's strategic repositioning for future growth and value creation," Kugan Sathiyanandarajah, KKR Partner.